MX378877B - Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo. - Google Patents

Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.

Info

Publication number
MX378877B
MX378877B MX2018013366A MX2018013366A MX378877B MX 378877 B MX378877 B MX 378877B MX 2018013366 A MX2018013366 A MX 2018013366A MX 2018013366 A MX2018013366 A MX 2018013366A MX 378877 B MX378877 B MX 378877B
Authority
MX
Mexico
Prior art keywords
culture
nitric oxide
oxide synthase
synthase inhibitors
inducible nitric
Prior art date
Application number
MX2018013366A
Other languages
English (en)
Inventor
Abraham Scaria
Jeffery Ardinger
Peter Pechan
Samuel Wadsworth
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX378877B publication Critical patent/MX378877B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a el uso de los inhibidores de iNOS, que incluyen el ácido aurintricarboxílico, la dexametasona y el ácido valproico, para aumentar el rendimiento de una variedad de virus en el cultivo, que incluyen los virus herpéticos recombinantes.
MX2018013366A 2013-01-08 2014-01-07 Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo. MX378877B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750175P 2013-01-08 2013-01-08
PCT/US2014/010553 WO2014110053A1 (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Publications (1)

Publication Number Publication Date
MX378877B true MX378877B (es) 2025-03-10

Family

ID=51167323

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008861A MX360470B (es) 2013-01-08 2014-01-07 Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.
MX2018013366A MX378877B (es) 2013-01-08 2014-01-07 Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015008861A MX360470B (es) 2013-01-08 2014-01-07 Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.

Country Status (20)

Country Link
US (2) US11299715B2 (es)
EP (3) EP3521420A1 (es)
JP (2) JP6534933B2 (es)
KR (1) KR102307279B1 (es)
CN (1) CN105008523B (es)
AR (1) AR094389A1 (es)
AU (1) AU2014205604B2 (es)
BR (2) BR112015016328B1 (es)
CA (1) CA2897444A1 (es)
DK (1) DK2943567T3 (es)
ES (1) ES2651763T3 (es)
HK (1) HK1249544A1 (es)
HU (1) HUE037482T2 (es)
IL (1) IL239824B (es)
MX (2) MX360470B (es)
NO (1) NO3050055T3 (es)
RU (1) RU2676733C2 (es)
SG (3) SG11201505333PA (es)
TW (1) TWI608102B (es)
WO (1) WO2014110053A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
FI3436593T3 (fi) 2016-03-28 2023-03-16 Ultragenyx Pharmaceutical Inc Adenoviruksen lämpöinaktivointimenetelmiä
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
PL3526321T3 (pl) 2016-10-14 2025-04-28 Ultragenyx Pharmaceutical Inc. Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami
WO2018175775A1 (en) 2017-03-22 2018-09-27 Dimension Therapeutics Cell culture methods involving hdac inhibitors or rep proteins
WO2018208960A1 (en) 2017-05-09 2018-11-15 Dimension Therapeutics, Inc. Scalable method for producing transfection reagents
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
CN110835622B (zh) * 2018-08-16 2021-04-27 上海药明生物技术有限公司 用于调节哺乳动物细胞乳酸代谢的培养基及其应用
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
AU2021239973A1 (en) 2020-03-16 2022-10-06 Ultragenyx Pharmaceutical Inc. Methods for enhancing recombinant adeno-associated virus yield
CN118871575A (zh) * 2022-02-21 2024-10-29 学校法人日本医科大学 病毒载体生产增强剂及产生病毒载体的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
RU2012335C1 (ru) * 1991-07-04 1994-05-15 Уфимский научно-исследовательский институт глазных болезней Ингибитор вируса простого герпеса
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1994003207A1 (en) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US6833271B2 (en) 1996-12-04 2004-12-21 Medi-Cult A/S Serum-free cell culture media
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6783972B1 (en) * 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7091029B2 (en) * 2002-09-23 2006-08-15 Applied Genetics Technologies Corporation High titer recombinant AAV production
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
CN100348718C (zh) * 2005-10-18 2007-11-14 中国人民解放军军事医学科学院生物工程研究所 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基
ES2533863T3 (es) * 2007-06-29 2015-04-15 Korea Research Institute Of Chemical Technology Inhibidores novedosos de la transcriptasa inversa de VIH

Also Published As

Publication number Publication date
HUE037482T2 (hu) 2018-08-28
KR102307279B1 (ko) 2021-09-29
CA2897444A1 (en) 2014-07-17
HK1214840A1 (en) 2016-08-05
US11299715B2 (en) 2022-04-12
MX2015008861A (es) 2016-04-13
MX360470B (es) 2018-11-05
KR20150103275A (ko) 2015-09-09
WO2014110053A1 (en) 2014-07-17
RU2676733C2 (ru) 2019-01-10
NO3050055T3 (es) 2018-02-10
DK2943567T3 (en) 2018-01-02
JP6534933B2 (ja) 2019-06-26
TWI608102B (zh) 2017-12-11
SG10201913130PA (en) 2020-03-30
EP3266866A1 (en) 2018-01-10
EP3266866B1 (en) 2019-03-06
JP2019187420A (ja) 2019-10-31
AR094389A1 (es) 2015-07-29
BR112015016328A2 (es) 2017-09-05
BR122020002822B1 (pt) 2023-04-18
EP2943567A1 (en) 2015-11-18
US20220340883A1 (en) 2022-10-27
SG11201505333PA (en) 2015-08-28
HK1249544A1 (en) 2018-11-02
AU2014205604A1 (en) 2015-08-13
EP2943567B1 (en) 2017-09-13
CN105008523B (zh) 2020-03-27
IL239824B (en) 2019-03-31
IL239824A0 (en) 2015-08-31
AU2014205604B2 (en) 2020-01-02
ES2651763T3 (es) 2018-01-29
JP2016504913A (ja) 2016-02-18
JP6837094B2 (ja) 2021-03-03
CN105008523A (zh) 2015-10-28
RU2018144779A (ru) 2019-01-29
RU2015133205A (ru) 2017-02-14
EP3521420A1 (en) 2019-08-07
BR112015016328B1 (pt) 2023-04-18
SG10201806715TA (en) 2018-09-27
US20150353899A1 (en) 2015-12-10
RU2018144779A3 (es) 2022-03-02
TW201446965A (zh) 2014-12-16

Similar Documents

Publication Publication Date Title
MX378877B (es) Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
IL231547B (en) A chimeric influenza virus hemagglutinin (ha) polypeptide,an immunogenic composition comprising same and uses thereof
NZ720885A (en) Rna transcription vector and uses thereof
IL230618A0 (en) Inhibitors of influenza viruses replication, compositions comprising the same and uses thereof
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
WO2014145599A3 (en) Recombinant virus and preparations thereof
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
MX2022011225A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
MX2016005956A (es) Anticuerpos especificos para fcrn.
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2018000164A1 (es) Vector recombinante del virus orf.
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112015017420A2 (pt) recombinação de vírus influenza
PL3022297T3 (pl) Stabilny genetycznie onkolityczny wirus rna, sposób jego wytwarzania i zastosowanie
BR112016007635A2 (pt) inibidores de nsp4 e métodos de uso
MY170453A (en) Etching material
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
EA201591933A1 (ru) Композиция с пониженной иммуногенностью